Loading clinical trials...

Microglia Activation in Asthma | Clinical Trials | Clareo Health

RECRUITING

Microglia Activation in Asthma

NCT04307667•University of Wisconsin, Madison

Summary

The goal of this clinical trail is to learn about how asthma influences brain function. The main questions it aims to answer are: * How airway inflammation in asthma affects the brain; and, * Whether airway inflammation in asthma is related to symptoms of depression and anxiety Over the course of 6 visits, participants will: * Complete questionnaires * Complete computer tasks * Undergo allergy skin test * Undergo breathing tests including two whole lung allergen challenges * Give four blood samples * Complete brain imaging scans

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Individuals with no health concerns that might affect the outcome of the study.
•Age 18-75 years of age.
•Physician diagnosis of asthma for at least six months prior to screening (can be determined at the discretion of an asthma/allergy physician member of the study team). Mild asthma will be defined as asthma that is well controlled with low-intensity treatment, e.g., SABA alone, as-needed low-dose ICS-LABA, or low-dose ICS plus as-needed SABA.
•At least a 20% decrease in forced expiratory volume (FEV1) during the immediate response following the screening inhaled allergen challenge.
•FEV1 ≥ 70% predicted at baseline.
•Positive immediate skin test for allergies to cat hair, house dust mite, or ragweed (historical data documented within the last 5 years with our research group is acceptable).
•Ability to tolerate a simulated MRI brain scanning session.
•In the opinion of the investigator, capable and willing to grant written informed consent and cooperate with study procedures and requirements.
•High-affinity TSPO-binding genotype. Mixed (high/low) binding-affinity genotype may be included at PIs discretion.

Exclusion Criteria

•Current smoker (defined as more than 0.5 pack per week for the past 6 months and any smoking within two weeks of study procedures) or has a smoking history exceeding 5 pack years within the last 10 years
•Currently receiving allergen immunotherapy
•Use of psychotropic medication that might affect function of neurocircuitry implicated in the investigator's hypotheses at the discretion of the PI or Co-Investigator (Co-I)
•Inability to hold medications detailed in the medication hold schedule
•Needle phobia or claustrophobia
•Major health problems such any of the following in the last 6 months: stroke/TIA, myocardial Infarction, stent placement, or acute coronary syndrome are definitively exclusionary. Decisions regarding other major health problems, such as autoimmune disease, history of carotid stenosis, heart disease, uncontrolled hypertension, lung diseases other than asthma, history of significant arrhythmias, etc. will be based upon the judgement of the PI/Co-I.
•Use of biologic medication that might affect signaling pathways under investigation (at the discretion of the PI/Co-I)
•Pre-existing chronic infectious disease
•Scheduled use of non-selective beta-blockers prior to each study visit
•Current use of beta-1 selective blockers (e.g., metoprolol, atenolol, acebutolol, betaxolol, esmolol, bisoprolo, and nebivolol)
+14 more criteria

Locations (1)

University of Wisconsin Madison

Madison, Wisconsin, United States

Key Dates

Start Date

December 17, 2019

Primary Completion Date

August 1, 2028

Completion Date

August 1, 2028

Last Updated

August 26, 2025

Enrollment

ESTIMATED participants

Conditions

Asthma

Interventions

Whole lung antigen challenge (WLAC)

BIOLOGICAL

[18F]FEPPA

RADIATION

Contacts

Rachel Kaspari

CONTACT

608-263-0524 maia@medicine.wisc.edu

Danika Klaus

CONTACT

608-263-0524 maia@medicine.wisc.edu

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Asthma ExacerbationsBiomarkers / Blood+1 more

View study

RECRUITING

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

NCT02327897

Asthma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 26, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Microglia Activation in Asthma

Inclusion Criteria

Exclusion Criteria

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma